Temozolomide induces senescence but not apoptosis in human melanoma cells

British Journal of Cancer

Volumn 97, Issue 9, 2007, Pages 1225-1233

  Mhaidat, N M ^a   Zhang, X D ^a   Allen, J ^c   Avery Kiejda, K A ^a   Scott, R J ^b   Hersey, P ^a,d  

^a Oncology and Immunology Unit   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d David Madison Clinical Sciences Building ^*  (Australia)

Author keywords

Apoptosis; Melanoma; p53; Senescence; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PIFITHRIN ALPHA; PROTEIN P53; TEMOZOLOMIDE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LYMPHOMA CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENESCENCE; SIGNAL TRANSDUCTION; WILD TYPE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BENZOTHIAZOLES; CELL AGING; CELL DIVISION; DACARBAZINE; G2 PHASE; HUMANS; LYMPHOMA; MELANOMA; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TOLUENE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35648934994     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604017     Document Type: Article

References (36)

1. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM (2002) Multifaceted resistance of gliomas to temozolomide. Clinical Cancer Res 8: 2725-2734
2. Bossi G, Sacchi A (2007) Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 29: 272-284
3. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D (1999) Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81: 1022-1030
4. Cozzi S, Parsons P, Ogbourne S, Pedley J, Boyle G (2006) Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res 66: 10083-10091
5. Culmsee C, Zhu X, Yu Q, Chan S, Camandola S, Guo Z, Greig N, Mattson M (2001) A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 77: 220-228
6. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, Jiricny J (1998) Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54: 334-341
7. Dimri G, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano E, Linskens M, Rubelj I, Pereira-Smith O (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367
8. Gillespie S, Zhang X, Hersey P (2004) Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. Mol Cancer Ther 3: 1651-1658
9. Gunther W, Pawlak E, Damasceno R, Arnold H, Terzis A (2003) Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br J Cancer 88: 463-469
10. Hagemann C, Blank J (2001) The ups and downs of MEK kinase interactions. Cell Signal 13: 863-875
11. Hirose Y, Berger M, Pieper R (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61: 1957-1963
12. Hussein M, Haemel A, Wood G (2003) Apoptosis and melanoma: molecular mechanisms. J Pathol 199: 275-288
13. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733-1737
14. Kroemer G, Reed JC (2000) Mitochondrial control of cell death. Nat Med 6: 513-519
15. Martin A, Odajima J, Hunt S, Dubus P, Ortega S, Malumbres M, Barbacid M (2005) Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 7: 591-598
16. 2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res 13: 1308-1314
17. Middlemas DS, Kirstein NM, Poquette C, Friedman HS, Houghton PJ, Brent TP (2000) Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6: 998-1007
18. Moll U, Zaika A (2001) Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett 493: 65-69
19. Nihal M, Ahmad N, Mukhtar H, Wood GS. (2005) Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 114: 513-521
20. Pepponi R, Marra G, Fuggetta MP, Falcinelli S, Pagani E, Bonmassar E, Jiricny J, D'Atri S (2003) The effect of O6-alkylguanine-DNA alkyl-transferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-Bis(2-chloroethyl)1-nitrosurea, and cisplatin. J Pharmacol Exp Ther 304: 661-668
21. Plummer ER, Middleton MR, Johnes C, Olsen A, Hickson L, McHugh P, Margison GP, McGown G, Thorncroft M, Watson AJ, Boddy AV, Calvert AH, Harris AL, Newell DR, Curtin NJ (2005) Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes o6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 11: 3402-3409
22. Probin V, Wang Y, Bai A, Zhou D (2006) Busulfan selectively induces cellular senescence but not apoptosis in WI38 fibroblasts via a p53-independent but extracellular signal-regulated kinase-p38 mitogen-activated protein kinase-dependent mechanism. J Pharmacol Exp Ther 319: 551-560
23. Schwarze S, Fu V, Desotelle J, Kenowski M, Jarrard D (2005) The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 7: 816-823
24. Sullivan A, Lu X (2007) ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer 96: 196-200
25. Tentori L, Lacal PM, Benincasa E, Franco D, Faraoni I, Bonmassar E, Graziani G (1998) Role of Wild-Type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase. J Pharmacol Exp Ther 285: 884-893
26. Tentori L, Orlando L, Lacal PM, Benincasa E, Faraoni I, Bonmassar E, D'Atri S, Graziani G (1997) Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 52: 249-258
27. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, Adams JM, Strasser A (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302: 1036-1038
28. Walsh G, Dewson G, Wardlaw A, Levi-Schaffer F, Moqbel R (1998) A comparative study of different methods for the assessment of apoptosis and necrosis in human eosinophils. J Immunol Methods 217: 153-163
29. Wang W, Yang X, Lopez de Silanes I, Carling D, Gorospe M (2003) Increased AMP: ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function. Biol Chem 278: 27016-27023
30. Wu J, Zhang X, Gillespie S, Hersey P (2005) Selection for TRAIL resistance in melanoma cells with high proliferative potential. FEBS Lett 579: 1940-1944
31. Xiang X, Saha A, Wen R, Ruderman N, Luo Z (2004) AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321: 161-167
32. Xu G, Mymryk J, Cairncross JG (2005) Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. Int J Cancer 116: 187-192
33. Zhang X, Franco A, Myers K, Gray C, Nguyen T, Hersey P (1999) Relation of TNF-related apoptosis-inducing ligand(TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59: 2747-2753
34. Zhang X, Zhang X, Nguyen D, Gray C, Hersey P (2001) Regulation of TRAIL-induced apoptosis of melanoma by release of Smac/DIABLO from mitochondria. Cancer Res 61: 7339-7348
35. Zhang XD, Wu JJ, Gillespie SK, Borrow JM, Hersey P (2006) Human melanoma cells selected for resistance to apoptosis by prolonged exposure to TRAIL are more vulnerable to necrotic cell death induced by Cisplatin. Clin Cancer Res 12: 1355-1364
36. Zong W, Ditsworth D, Bauer D, Wang Z, Thompson C (2004) Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 18: 1272-1282